Skip to main content
SpringerLink
Log in

Chemotherapy of Drug-Resistant Tuberculosis In the Context of Developed and Developing Countries

  • Chapter
Mycobacteria

Part of the book series: Chapman & Hall Medical Microbiology Series ((CHMMS))

Abstract

Tuberculosis, once a dreadful disease, has become a curable disease mainly due to marked progress in chemotherapy. Therefore, the emergence of drug resistance is one of the major problems of current tuberculosis control programs. Drug-resistant tuberculosis is produced by poor case management and the cost of treatment of drug-resistant cases is much higher than that for drug-sensitive cases. In addition, its efficacy is generally poorer. Thus, the priority of a national tuberculosis control program should be to achieve a high cure rate of newly detected tuberculosis by improving case management through various measures, such as directly observed therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kudoh S (1975) Tubercle bacilli. In: Shimao T, ed. A New Introduction to Phthisiology, pp. 75–95. Tokyo: Japan Anti-Tuberculosis Association.

    Google Scholar 

  2. East African/British Medical Research Council (1973) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet 7816:1331–1339.

    Google Scholar 

  3. East African/British Medical Research Council (1974) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet 7875:237–240.

    Google Scholar 

  4. Second East African/British Medical Research Council Study (1974) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 7889:1100–1115.

    Google Scholar 

  5. Second East African/British Medical Research Council Study (1976) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Am Rev Resp Dis 114:471–475.

    Google Scholar 

  6. Third East African/British Medical Research Council Study (1978) Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. First report. Am Rev Resp Dis 118:39–48.

    Google Scholar 

  7. Third East AfricanBritish Medical Research Council Study (1980) Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Tubercle 61:59–69.

    Article  Google Scholar 

  8. East and Central African/British Medical Research Council Fifth Collaborative Study (1986) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Final report. Tubercle 67:5–15.

    Article  Google Scholar 

  9. Hong Kong Chest Service/British Medical Research Council (1978) Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Resp Dis 118:219–227.

    Google Scholar 

  10. Hong Kong Chest Service/British Medical Research Council (1979) Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. The results up to 24 months. Tubercle 60:201–210.

    Article  Google Scholar 

  11. Tanzania/British Medical Research Council Study (1985) Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Resp Dis 131:727–731.

    Google Scholar 

  12. Singapore Tuberculosis Service/British Medical Research Council (1985) Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Resp Dis 132:374–378.

    Google Scholar 

  13. The Committee on Treatment of the International Union Against Tuberculosis (1969) A comparison of regimens of ethionamide, pyrazinamide and cycloserine in the retreatment of patients with pulmonary tuberculosis. Bull IUAT 42:7–57.

    Google Scholar 

  14. Hong Kong Tuberculosis Treatment Services/British Medical Research Council (1975) A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: Results up to 30 months. Tubercle 56:179–189.

    Article  Google Scholar 

  15. Zierski M (1977) Prospects of retreatment of chronic resistant pulmonary tuberculosis patients. A critical review. Lung 154:91–102.

    Article  PubMed  CAS  Google Scholar 

  16. Goble M, Iseman M, Madsen LA, et al. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328:527— 532.

    Article  PubMed  CAS  Google Scholar 

  17. Tuberculosis Research Committee, RYOKEN/Oka H, Oomori K (1962) A study on clinical efficacy of the combination of KM, Th and CS for severe pulmonary tuberculosis resistant to primary drugs. Results of treatment for 12 months. Nihon Iji Shimpo (Japan Med J) 1997:3–14.

    Google Scholar 

  18. Tuberculosis Research Committee, RYOKEN/Oka H, Oomori K (1963) Follow-up results of patients with severe pulmonary tuberculosis treated with the combination of KM, Th and CS. Nihon Iji Shimpo (Japan Med J) 2061:14–18.

    Google Scholar 

  19. Tuberculosis Research Committee, RYOKEN (1970) Therapeutic effect of rifampicin on re-treatment cases of pulmonary tuberculosis. Kekkaku (Tuberculosis) 45:227–235.

    Google Scholar 

  20. Tuberculosis Research Committee, RYOKEN (1974) Three-year follow-up results of the first clinical study on the daily and twice-weekly administration of rifampicin, investigated by the Tuberculosis Research Committee, RYOKEN. Kekkaku (Tuberculosis) 49:107–112.

    Google Scholar 

  21. Saitoh M (1983) Infectiousness of chronic bacillary cases of pulmonary tuberculosis and problems on contacts control. Hokenfu no Kekkaku Tenbou (Rev Tuber Publ Hlth Nurses) 22:48–58.

    Google Scholar 

  22. Tuberculosis Research Committee, RYOKEN/Oka H, Gomi J, Chiba Y, et al. (1969) Prevalence of drug resistance among pulmonary tuberculosis patients newly admitted to member’s institutions. The results in 1966 compared with those of 1957, 1959, 1961 and 1963. Nihon Iji Shimpo (Japan Med J) 2355:3–8.

    Google Scholar 

  23. Tuberculosis Research Committee, RYOKEN /Oka H, Gomi J, Chiba Y, et al. (1975) Prevalence of drug resistance among pulmonary tuberculosis patients newly admitted to member’s institutions. Part 1. The results in 1972 compared with those of previous 6 surveys. Kekkaku (Tuberculosis) 50:1–8.

    Google Scholar 

  24. Tuberculosis Research Committee, RYOKEN (1985) Follow-up study of patients with tuberculosis staying at hospitals for more than five years by the time of survey in 1975 (Part 1). Results of the survey in 1981, with special reference to the dead and discharged patients. Kekkaku (Tuberculosis) 60:351–403.

    Google Scholar 

  25. Tuberculosis Research Committee, RYOKEN (1984) Three years’ follow-up study of patients with tuberculosis staying at hospitals for more than three years in 1981. Annual Report of RYOKEN for 1984, pp 4–16.

    Google Scholar 

  26. Tuberculosis Research Committee, RYOKEN (1991) Two years’ follow-up study of patients with tuberculosis staying at hospitals for more than two years in 1988. Annual Report of RYOKEN for 1991, pp. 5–13.

    Google Scholar 

  27. Kino C (1961) A survey on deaths in 1959 among tuberculosis patients admitted to national sanatoria in whole Japan. Kekkaku Kenkyu no Shimpo (Adv Tuber Res) 30:170–214.

    Google Scholar 

  28. TB Death Survey Teams of National Sanatoria and of Japan Anti-Tuberculosis Association (JATA) (1967) A survey on deaths in 1964 among tuberculosis patients admitted to national sanatoria in whole Japan. Kekkaku to Kokyuki Shikkan Bunken no Shouroku Sokuhou (Abstr Curr Liter Tuberc Respir Dis) 18:42–60.

    Google Scholar 

  29. TB Death Survey Teams of National Sanatoria and of JATA (1971) A survey on deaths in 1969 among tu berculos is pat ie nt s admitted to national sanatoria in whole Japan. Kekkaku to Kokyuki Shikkan Bunken no Shouroku Sokuhou (Abst Curr Liter Tuberc Respir Dis) 22:571–590.

    Google Scholar 

  30. TB Death Survey Teams of National Sanatoria and of JATA (1976) A survey on deaths in 1974 among tuberculosis patients admitted to national sanatoria in whole Japan. Kokyuki Shikkan to Kekkaku Bunken no Shouroku Sokuhou (Abstr Curr Liter Tuberc Respir Dis) 27:575–590.

    Google Scholar 

  31. TB Death Survey Teams of National Sanatoria and of JATA (1981) A survey on deaths in 1979 among tuberculosis patients admitted to national sanatoria in whole Japan. Kokyuki Shikkan to Kekkaku Bunken no Shouroku Sokuhou (Abst Curr Liter Tuberc Respir Dis) 32:393–401.

    Google Scholar 

  32. TB Death Survey Teams of National Sanatoria and of JATA (1987) A survey on deaths in 1984 among tuberculosis patients admitted to national sanatoria in whole Japan. Kokyuki Shikkan to Kekkaku Bunken no Shouroku Sokuhou (Abstr Curr Liter Tuberc Respir Dis) 38:57–87.

    Google Scholar 

  33. TB Death Survey Team of National Sanatoria (1992) A survey on deaths in 1989 among tuberculosis patients admitted to national sanatoria in whole Japan. Shiryo to Tebou (Inform Rev Tuberc Respir Dis Res) 1:59–86.

    Google Scholar 

  34. Tuberculosis Research Committee, RYOKEN and Its Subcommittee on Surgical Treatment (1984) Changes in surgical treatment for pulmonary tuberculosis in recent 6 years. A comparative study between preoperative culture positive and negative cases. Kekkaku (Tuberculosis) 59:467–474.

    Google Scholar 

  35. World Health Organization (1993) Treatment of Tuberculosis. Guidelines for National Programmes, pp. 1–43. Geneva: World Health Organization.

    Google Scholar 

Download references

Authors
  1. Tadao Shimao
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chicago College of Medicine, University of Illinois, Chicago, Illinois, USA

    Pattisapu R. J. Gangadharam Ph.D. (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research) (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research)

  2. Public Health Laboratory Service, University Hospital of Wales, UK

    P. Anthony Jenkins Ph.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Shimao, T. (1998). Chemotherapy of Drug-Resistant Tuberculosis In the Context of Developed and Developing Countries. In: Gangadharam, P.R.J., Jenkins, P.A. (eds) Mycobacteria. Chapman & Hall Medical Microbiology Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-7511-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-7511-5_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-7513-9

  • Online ISBN: 978-1-4615-7511-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation